Relay Therapeutics (NASDAQ:RLAY) CFO Sells $14,375.88 in Stock

Relay Therapeutics, Inc. (NASDAQ:RLAY) CFO Thomas Catinazzo sold 972 shares of the company’s stock in a transaction that occurred on Tuesday, April 28th. The stock was sold at an average price of $14.79, for a total value of $14,375.88. Following the completion of the transaction, the chief financial officer owned 212,895 shares of the company’s stock, valued at approximately $3,148,717.05. This represents a 0.45% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Thomas Catinazzo also recently made the following trade(s):

• On Tuesday, April 7th, Thomas Catinazzo sold 17,717 shares of Relay Therapeutics stock. The stock was sold at an average price of $13.01, for a total value of $230,498.17.
• On Thursday, April 9th, Thomas Catinazzo sold 1,800 shares of Relay Therapeutics stock. The stock was sold at an average price of $15.00, for a total value of $27,000.00.

Relay Therapeutics Stock Down 1.9%

NASDAQ RLAY opened at $12.72 on Friday. The stock has a market cap of $2.43 billion, a PE ratio of -7.85 and a beta of 1.74. Relay Therapeutics, Inc. has a fifty-two week low of $2.67 and a fifty-two week high of $17.32. The business has a 50 day moving average price of $11.87 and a two-hundred day moving average price of $9.15.

Relay Therapeutics (NASDAQ:RLAY) last released its quarterly earnings results on Thursday, February 26th. The company reported ($0.32) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.38) by $0.06. The company had revenue of $7.00 million during the quarter, compared to analysts’ expectations of $4.34 million. Sell-side analysts anticipate that Relay Therapeutics, Inc. will post -1.51 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the company. Oppenheimer upped their price target on Relay Therapeutics from $14.00 to $18.00 and gave the stock an “outperform” rating in a report on Tuesday. Citigroup reaffirmed an “outperform” rating on shares of Relay Therapeutics in a research report on Tuesday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Relay Therapeutics in a research report on Wednesday, April 8th. Barclays upped their target price on Relay Therapeutics from $17.00 to $21.00 and gave the company an “overweight” rating in a research report on Wednesday, April 8th. Finally, Citizens Jmp upped their target price on Relay Therapeutics from $17.00 to $19.00 and gave the company a “market outperform” rating in a research report on Tuesday, April 28th. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Relay Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $20.56.

Hedge Funds Weigh In On Relay Therapeutics

A number of institutional investors have recently made changes to their positions in RLAY. Torren Management LLC acquired a new position in shares of Relay Therapeutics in the 4th quarter valued at approximately $30,000. Smartleaf Asset Management LLC raised its position in shares of Relay Therapeutics by 288.6% in the 4th quarter. Smartleaf Asset Management LLC now owns 4,426 shares of the company’s stock valued at $37,000 after purchasing an additional 3,287 shares in the last quarter. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Relay Therapeutics during the 4th quarter valued at approximately $46,000. Captrust Financial Advisors acquired a new stake in shares of Relay Therapeutics during the 2nd quarter valued at approximately $49,000. Finally, Cerity Partners LLC acquired a new stake in shares of Relay Therapeutics during the 2nd quarter valued at approximately $51,000. 96.98% of the stock is owned by institutional investors and hedge funds.

Relay Therapeutics Company Profile

Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins.

The company’s core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening.